Part B Demo Comments Overwhelmingly Negative, Uniform In Content
Executive Summary
More than 90% of comments submitted on proposed Medicare payment experiment for Part B drugs were negative, and most were submitted by patients and health care providers.
You may also be interested in...
Biden Administration May Push Rx Pricing To Back Burner With Senate That Stays Pharma Friendly
A Biden Administration with near-term priorities other than drug pricing and a Republican-controlled Senate dedicated to blocking any legislation that would enact government price controls is a relatively positive outcome for industry.
Biden Administration May Push Rx Pricing To Back Burner With Senate That Stays Pharma Friendly
A Biden Administration with near-term priorities other than drug pricing and a Republican-controlled Senate dedicated to blocking any legislation that would enact government price controls is a relatively positive outcome for industry.
Biden's Drug Pricing Administrative Actions Could Focus On Medicare Demos
Center for American Progress suggests pricing reforms for the 'next Administration' in lieu of legislation.